Best Life Sciences Companies To Buy Right Now

Following up on a strong earnings report from Wednesday, hi-tech glassmaker Corning (NYSE: GLW  ) offered further details this morning on its plans for the future.

Specifically, Corning announced plans to capitalize upon a coming wave in new environmental regulation of heavy-duty engines in Europe and China, by investing similarly heavily in its production of diesel emissions control products.

Corning says it will spend about $250 million on capital improvements in its Environmental Technologies�&�Life Sciences�Business Group, hoping to double its revenues from the group by 2017. Corning will spend to increase capacity at its Erwin diesel facility, which manufactures large ceramic substrates and filters for heavy-duty diesel engine, truck, construction, and agricultural equipment manufacturers.

However, all this new spending will not affect Corning's forecast for 2013 capital expenditures, the company assured investors. Yesterday, Corning pegged 2013 capex spending at approximately $1.3 billion, down from last year's $1.8 billion. With investments in clean diesel being spread out over the next three years, Corning has already figured this investment into capital spending projections for 2013 and 2014. The company gave no such assurances for 2015, however, when the expanded diesel facilities should go into operation.

Best Life Sciences Companies To Buy Right Now: Inca Minerals Ltd (ICG)

Inca Minerals Limited, formerly Condor Metals Limited, is an Australia-based exploration company. During the fiscal year ended June 30, 2011 (fiscal 2011), the Company's principal activities were conducting exploration and evaluation work on its existing tenements, as well as seeking out additional tenements. It focuses on nickel, iron, manganese and base metals exploration in Australia. During fiscal 2011, it concentrated on the Kallona iron and manganese prospect in the East Pilbar, where the first drilling was commenced in June 2011. Results received confirmed the presence of manganese, along with consistent iron intersections. The Company also continued to explore on the Dingo Range tenements south east of Wiluna. Advisors' Opinion:

• [By Fede Zaldua]

  For its third quarter, Citi reported net earnings of $3.2 billion or Earnings Per Share (EPS) of $1, which was just below consensus expectations of $1.02 per share. The bank explained its poor performance through lower than expected earnings at the Institutional Clients Group (ICG) division (mainly trading activities in equities, commodities and fixed income) but also lower Consumer Banking revenues on weaker mortgage results. Its extremely relevant to stress that third quarter ICG and mortgage related results came weaker than expected at most banking institutions, including JP Morgan (JPM) and almighty Goldman Sachs (GS). On my opinion, much more relevant metrics (because they can be more directly affected by management's decisions) such as those metrics related to expenses and credit quality came in line with expectations.

Best Life Sciences Companies To Buy Right Now: Pharmacyclics Inc (PCYC)

Pharmacyclics, Inc., incorporated on April 19, 1991, is a clinical-stage biopharmaceutical company focused on developing and commercializing small-molecule drugs for the treatment of cancer and immune mediated diseases. The Company's clinical development and product candidates are small-molecule enzyme inhibitors designed to target biochemical pathways involved in human diseases. As of June 30, 2011, it had three drug candidates under clinical development and a number of preclinical lead molecules. This includes an inhibitor of Bruton�� tyrosine kinase (Btk) (PCI-32765) in Phase II studies in hematologic malignancies; a Btk inhibitor lead optimization program targeting autoimmune indications, an inhibitor of Factor VIIa (PCI-27483) in a Phase II clinical trial in pancreatic cancer, and a histone deacetylase (HDAC) inhibitor (PCI-24781) in Phase I and II clinical trials in solid tumors and hematological malignancies as of June 30, 2012.

As of June 30, 2012, the Company developed ibrutinib, which has demonstrated clinical activity and tolerability in Phase I and Phase II clinical trials in a variety of B-cell malignancies, including chronic lymphocytic leukemia (CLL) and a number of non-Hodgkin�� lymphoma (NHL) subtypes. CLL, mantle cell lymphoma (MCL), follicular lymphoma (FL), diffuse B-cell lymphoma (DLBCL) and multiple myeloma (MM) are specific indications of its current or planned Phase Ib/II and Phase III development program. had development programs for B-cell malignancies and autoimmune diseases. For malignant indications it has developed PCI-32765, which has demonstrated clinical activity and tolerability in Phase I and Phase II clinical trials in a range of B-cell malignancies, including chronic lymphocytic leukemia (CLL) and a number of non-Hodgkin�� lymphoma (NHL) subtypes. CLL, mantle cell lymphoma (MCL), follicular lymphoma (FL), diffuse large B cell lymphoma (DLBCL) and multiple myeloma (MM) are specific indications of its Phase II development. It has developed an assay! to measure occupancy of Btk in PBMCs using a cell-permeable fluorescently-labeled derivative of PCI-32765.

Factor VII is an enzyme that becomes activated (FVIIa) by binding to the cell surface protein tissue factor (TF), a protein found in the body that helps to trigger the process of blood clotting in response to injury. TF is over expressed in many cancers including gastric, breast, colon, lung, prostate, ovarian and pancreatic cancers. In these tumors, the FVIIa/TF complex induces intracellular signaling pathways by activating protease activated receptor 2 (PAR-2), another cell-surface protein. This in turn increases the expression of interleukin-8 (IL-8), a protein produced by white blood cells and other immune cells in response to pathogenic stimulation, and vascular endothelial growth factor (VEGF), a signal protein produced by cells that stimulate the growth of blood vessels. Both proteins play an important role in tumor growth and metastases as well as angiogenesis (growth of new blood vessels). FVIIa/TF complex also initiates the coagulation (a process by which blood forms clots) processes implicated in the high incidence of thromboembolic (the process by which the blood clots within a blood vessel) complications seen in patients with TF-expressing cancers. Thromboembolic events are a cause of death in patients with cancer and anticoagulant treatment has been shown to improve survival in a variety of cancers (Klerk et al. JCO. 2005).

PCI-27483 Factor VIIa Inhibitor

The Company�� Factor VIIa inhibitor PCI-27483 is a first-in-human small molecule inhibitor that selectively targets FVIIa. As an inhibitor of FVIIa, PCI-27483 has two potential mechanisms of action: inhibition of intracellular signaling involved in tumor growth and metastases and inhibition of early coagulation processes associated with thromboembolism.

Factor VIIa PCI-27483 Clinical Development Update

A multicenter Phase I/II of PCI-27483 in patients with locally a! dvanced o! r metastatic pancreatic cancer that are either receiving or are planned to receive gemcitabine therapy has completed enrollment. The Phase II portion of the study randomized patients to receive either gemcitabine alone or gemcitabine plus PCI-27483 (1.2 mg/kg twice daily). The objectives are to assess the safety of FVIIa Inhibitor PCI-27483 at pharmacologically active dose levels, to assess potential inhibition of tumor progression and to obtain initial information of the effects on the incidence of thromboembolic events. Due to a paradigm shift away from the use of gemcitabine alone for the treatment of pancreatic cancer, enrolling patients in this randomized study has been challenging. PCYC is evaluating other alternatives for development of this agent.

A multicenter Phase I/II of PCI-27483 in patients with locally advanced or metastatic pancreatic cancer that are either receiving or are planned to receive gemcitabine therapy has completed enrollment. The Phase II portion of the study randomized patients to receive either gemcitabine alone or gemcitabine plus PCI-27483 (1.2 mg/kg twice daily). PCI-27483 is covered by United States patents and patent applications and counterpart patents and patent applications in fourteen ex-United States territories, including Europe, Canada, Mexico, Japan, China, India, South Korea, Australia and Brazil.

Advisors' Opinion:

• [By Anders Bylund]

  And then there's cancer drug developer Pharmacyclics (NASDAQ: PCYC  ) . This stock had been trading like a roller coaster when the poison pill quietly got the kibosh, and continued to trade sideways for another couple of years. Then Pharmacyclics' cancer treatments made some headway in FDA proceedings led by leukemia drug Ibrutinib, sending the stock on a rocket ride. Pharmacyclics' returns of 2,500% since the plan change make the S&P 500's 45% jump look like dead money. And Pharmacyclics may work together with some big partners, but remains a separate business to this day.

• [By Dan Caplinger]

  Yet J&J isn't satisfied with what it already has. Last week, the company joined with Pharmacyclics (NASDAQ: PCYC  ) to seek approval for their lymphoma drug ibrutinib. J&J will get a 50% share of any profit from the venture, and J&J cited a Piper Jaffray estimate that just one of its indications could produce sales of more than $4 billion.

• [By Jon C. Ogg]

  Pharmacyclics Inc. (NASDAQ: PCYC) was started as Overweight with a $142 price target at J.P. Morgan. Deutsche Bank also started it with a Buy rating and a $170 price target.

Hot Rising Stocks To Own For 2015: Market Vectors Steel ETF (SLX)

Market Vectors Steel ETF (the Fund) seeks to replicate as closely as possible the price and yield performance of the NYSE Arca Steel Index (STEEL or the Index) by investing in a portfolio of securities that generally replicates STEEL. STEEL, calculated by the NYSE Alternext, is a modified market capitalization-weighted index consisting of publicly traded companies predominantly involved in the production of steel products or mining and processing of iron ore. The Index includes companies primarily involved in a variety of activities related to steel production, including the operation of manufacturing mills and fabrication of steel products. Companies eligible for inclusion in Index should be engaged in solar power and related products and services, deriving at least 66% of revenues from it with market cap exceeding $100 million, and should have three-month trading volume equal to or greater than $1 million per day. Its investment advisor is Van Eck Associates Corporation. Advisors' Opinion:

• [By John Udovich]

  On Monday, Goldman Sachs upgraded the whole steel sector from Cautious to Neutral and specifically upgraded small cap and mid cap steel stocks AK Steel Holding Corporation (NYSE: AKS), United States Steel Corporation (NYSE: X) and Steel Dynamics Inc. (NASDAQ: STLD) to Buy with price targets of $6, $30 and $22, respectively, but should you go for one of these individual steel stocks or for the Market Vectors Steel ETF (NYSEARCA: SLX)? To begin with, Goldman Sachs says that the�supply-demand fundamentals for steel are starting to look more appealing as some supply has been taken out plus they have a very bearish view on input costs (as in iron ore)���which bodes well for steel producers in the long run. Moreover, recently filed trade cases could provide some tailwind���if they are successful.�Of course a rising tide can lift all ships, but Goldman Sachs suggests that you go for the following�small cap or mid cap steel stocks:�

• [By Ben Levisohn]

  In our late October report on X, we noted the Company was “scratching the surface” on operational improvement, and we expected shares to edge higher over the near term. While X shares have appreciated by 16% since that report vs. the S&P 500 of +4% and the [Market Vectors Steel ETF (SLX)] of +3%, we believe shares have more room to run based on our positive carbon hot-rolled steel pricing revisions for 2014: meaningful raw material cost tailwinds (coal, scrap, iron ore); low Street EPS and EBITDA expectations for 2014-2015; an ever-increasing interest rate environment (benefits for pension exposure); more evidence of European macro stability; and above-average likelihood of incremental operational efficiency announcements such as a joint venture or tolling agreement with Allegheny Technologies Incorporated (ATI).

Best Life Sciences Companies To Buy Right Now: ACE Ltd (ACE)

ACE Ltd (ACE) is a holding company of the ACE Group of Companies. ACE is a global insurance and reinsurance organization, serving the needs of customers in more than 170 countries. It offers commercial insurance products and service offerings, such as risk management programs, loss control and engineering and complex claims management. It also provides specialized insurance products ranging from Directors & Officers (D&O) and professional liability to various specialty-casualty and umbrella and excess casualty lines to niche areas, such as aviation and energy. In addition, it supplies personal accident, supplemental health, and life insurance to individuals in select countries. ACE operates in four business segments: Insurance-North American, Insurance-Overseas General, Global Reinsurance, and Life. In December 2011, it acquired Rio Guayas Compania de Seguros y Reaseguros, a general insurance company in Ecuador. On November 30, 2011, it acquired Penn Millers Holding Corporation (PMHC). On April 1, 2011, it acquired the operations of New York Life�� Hong Kong. On February 1, 2011, ACE acquired New York Life�� Korea operations. In September 2012, it acquired 80% of PT Asuransi Jaya Proteksi in Indonesia.

Insurance-North American

ACE�� Insurance-North American segment consists of the operations in the United States, Canada, and Bermuda. This segment includes the operations of ACE USA (including ACE Canada), ACE Bermuda, ACE Commercial Risk Services, ACE Private Risk Services, ACE Westchester, ACE Agriculture, and various run-off operations. During the year ended December 31, 2011, Insurance-North American segment accounted for 45% of its consolidated net premiums earned. During 2011, ACE USA represented approximately 49% of Insurance-North American�� net premiums earned.

ACE USA is the North American retail operating division which provides a broad array of P&C, A&H, and risk management products and services to a diverse group of commercial and non-commercia! l enterprises and consumers. ACE Bermuda provides commercial insurance products on an excess basis mainly to a global client base, covering exposures that are generally low in frequency and high in severity. ACE Commercial Risk Services addresses the insurance needs of small to mid-sized businesses in North America by delivering an array of specialty product solutions for targeted industries. ACE Private Risk Services provides personal lines coverages for high net worth individuals and families in North America.

ACE Westchester specializes in the North American wholesale distribution of excess and surplus P&C, environmental, professional and inland marine products. ACE Agriculture provides Multi-Peril Crop Insurance and crop/hail insurance protection to customers throughout the United States and Canada through Rain and Hail and Agribusiness insurance through Penn Millers Insurance Company. The run-off operations include Brandywine, Commercial Insurance Services, residual market workers��compensation business, pools and syndicates not attributable to a single business group, and other exited lines of business. Run-off operations do not actively sell insurance products, but are responsible for the management of existing policies and settlement of related claims.

Insurance-Overseas General

During 2011, ACE�� Insurance- Overseas General segment accounted for 37% of its consolidated net premiums earned. Insurance-Overseas General segment consists of ACE International, its global retail insurance operations, the wholesale insurance business of ACE Global Markets, and the international A&H and life business of Combined Insurance. ACE International is its retail business serving local companies and insureds to large multinationals outside the United States, Bermuda, and Canada. ACE Global Markets, its London-based excess and surplus lines business, includes Lloyd�� of London (Lloyd��) Syndicate 2488 (Syndicate 2488). ACE provides a fund at Lloyd�� to support und! erwriting! by Syndicate 2488, which is managed by ACE Underwriting Agencies Limited. The reinsurance operation of ACE Global Markets is included in the Global Reinsurance segment.

Property insurance products include traditional commercial fire coverage, as well as energy industry-related, construction, and other technical coverages. Principal casualty products are commercial primary and excess casualty, environmental, marine and general liability. ACE International specialty coverages include D&O professional indemnity, energy, aviation, political risk and specialty personal lines products. The A&H operations primarily offer personal accident and supplemental medical products to meet the insurance needs of individuals and groups outside of United States insurance markets. ACE International�� personal lines operations provide specialty products and services designed to meet the needs of specific target markets and include property damage, auto, homeowners, and personal liability.

Global Reinsurance

During 2011, ACE�� Global Reinsurance segment, which accounted for 7% of its consolidated net premiums earned. Global Reinsurance segment represents ACE�� reinsurance operations comprising ACE Tempest Re Bermuda, ACE Tempest Re USA, ACE Tempest Re International, and ACE Tempest Re Canada. The Global Reinsurance segment also includes ACE Global Markets��reinsurance operations. Global Reinsurance markets its reinsurance products worldwide under the ACE Tempest Re brand name and provides a range of coverage to a diverse array of primary P&C companies. ACE Tempest Re Bermuda principally provides property catastrophe reinsurance, on an excess of loss basis globally to insurers of commercial and personal property. ACE Tempest Re Bermuda underwrites reinsurance principally on an excess of loss basis, meaning that its exposure only arises after the ceding company�� accumulated losses have exceeded the attachment point of the reinsurance policy. ACE Tempest Re Bermuda also writes ! other typ! es of reinsurance on a limited basis for selected clients.

ACE Tempest Re USA writes all lines of traditional and specialty P&C reinsurance for the United States market, principally on a treaty basis, with a focus on writing property per risk and casualty reinsurance. ACE Tempest Re USA underwrites reinsurance on both a proportional and excess of loss basis. ACE Tempest Re International provides P&C treaty reinsurance to insurance companies worldwide. ACE Tempest Re Canada offers an array of traditional and specialty P&C reinsurance to the Canadian market, including casualty, property risk and property catastrophe.

Life

During 2011, ACE�� Life accounted for 11% of 2011 consolidated net premiums earned. Life includes ACE�� international life operations (ACE Life), ACE Tempest Life Re (ACE Life Re), and the North American supplemental A&H and life business of Combined Insurance. ACE Life provides individual life and group insurance, including Egypt, Indonesia, Taiwan, Thailand, Vietnam, the United Arab Emirates, throughout Latin America, selectively in Europe, as well as China through a non-consolidated joint venture insurance company.

ACE Life offers a portfolio of protection and savings products, including whole life, endowment plans, individual term life, group term life, group medical, personal accident, universal life, and unit linked contracts. ACE Life sells to consumers through a range of distribution channels, including agency, bancassurance, brokers, and direct to consumer marketing. ACE Life Re helps clients (ceding companies) manage mortality, morbidity, and lapse risks embedded in their books of business. ACE Life Re�� business is a Bermuda-based operation, which provides reinsurance to primary life insurers, focusing on guarantees included in certain fixed and variable annuity products and also on more traditional mortality reinsurance protection. ACE Life Re is a United States-based traditional life reinsurance operation. Combined I! nsurance ! distributes specialty individual accident and supplemental health and life insurance products targeted to middle income consumers in the United States and Canada.

Advisors' Opinion:

• [By gurujx]

  ACE Ltd (ACE) Reached the 52-Week High of $104.92

  ACE Ltd is a holding company which, until July 18, 2008, was incorporated with limited liability under the Cayman Islands Companies law. Ace Ltd has a market cap of $35.43 billion; its shares were traded at around $104.92 with a P/E ratio of 10.20 and P/S ratio of 1.86. The dividend yield of Ace Ltd stocks is 2.17%. Ace Ltd had an annual average earnings growth of 7.20% over the past 10 years. GuruFocus rated Ace Ltd the business predictability rank of 2-star.

• [By Damian Illia]

  ACE Limited (ACE) is an insurance and reinsurance organization. The company provides commercial insurance products and service offerings such as risk management programs, loss control and engineering and complex claims management. The company�� segments are: Insurance - North American, Insurance - Overseas General, Global Reinsurance, and Life.

• [By Dividends4Life]

  This week a few companies answered the call and rewarded their shareholders with higher cash dividends:
  
  Consolidated Edison Inc. (ED) engages in regulated electric, gas, and steam delivery businesses. January 16th the company increased its quarterly dividend 2.4% to $0.63 per share. The dividend is payable March 15, 2014, to stockholders of record on February 12, 2014. The yield based on the new payout is 4.7%.
  
  Cousins Properties Incorporated (CUZ), a real estate investment trust (REIT), owns, develops, and manages real estate portfolio, as well as performs certain real estate-related services. January 16th the company increased its quarterly dividend 66.7% to $0.075 per share. The dividend is payable February 24, 2014, to stockholders of record on February 10, 2014. The yield based on the new payout is 2.8%.
  
  Wisconsin Energy Corporation (WEC) generates and distributes electric energy, as well as distributes natural gas. The company operates in two segments, Utility Energy and Non-Utility Energy. January 16th the company increased its quarterly dividend 2% to $0.3900 per share. The dividend is payable March 1, 2014, to stockholders of record on February 14, 2014. The yield based on the new payout is 3.8%.
  
  BlackRock Inc. (BLK) is a publicly owned investment manager. The firm primarily provides its services to institutional, intermediary, and individual investors. January 16th the company increased its quarterly dividend 14.9% to $1.93 per share. The dividend is payable March 24, 2014, to stockholders of record on March 7, 2014. The yield based on the new payout is 2.4%.
  
  ONEOK Inc. (OKE) operates as a diversified energy company in the United States. January 15th the company increased its quarterly dividend 5.3% to $0.40 per share. The dividend is payable February 18, 2014, to stockholders of record on February 10, 2014. The yield based on the new payout is 2.5%.
  
  Omega Healthcare Investors Inc. (OHI) is a real es

• [By Ben Levisohn]

  JPMorgan Chase (JPM) and American Express (AXP) rose 2% and 2.1%, respectively, as financial stocks gained on speculation that the jobless claims data would spur the Federal Reserve to taper sooner rather than later, while Ace Ltd.�(ACE) rose 3.8%. �General Motors�(GM) gained 1.1% after the US government said it could sell the last of its shares by year-end. On the downside, Target (TGT) fell 3.5% after reporting earnings that missed analyst expectations.

Best Life Sciences Companies To Buy Right Now: Fair Isaac Corp (FICO)

Fair Isaac Corporation (FICO), incorporated on May 15, 1987, provides products and services that enable businesses to automate, improve and connect decisions to enhance business performance. The Company operates in three segments: Applications, which include pre-configured Decision Management applications designed for a specific type of business problem or process; Scores, which includes the Company's business-to-business scoring solutions and services, its myFICO solutions for consumers, and associated professional services, and Tools segment, which include software tools that clients can use to create their own custom Decision Management applications, as well as associated professional services. In May 2012, the Company acquired Entiera Inc. In September 2012, it acquired Adeptra Ltd. On April 1, 2013, FICO acquired Infoglide Software Corp.

Applications

The Company develops industry-tailored Decision Management applications, categorized as Applications, which apply analytics, data management and Decision Management software to specific business challenges and processes. These include credit offer prescreening, insurance claims management and others. The Company's Applications primarily serve clients in the banking, insurance, healthcare, and retail sectors. The chief offerings for marketing are the Company's FICO Analytic Offer Manager and FICO Customer Dialogue Manager. These solutions offer a suite of products, capabilities and services designed to integrate the technology and analytic services needed to perform context-sensitive customer acquisition, cross-selling and retention programs and deliver mathematically optimized offers.

The Company provides solutions that enable banks, credit unions, finance companies, installment lenders and other companies to automates and improve the processing of requests for credit or service. The Company provides customer management solutions for banking, where it�� account and customer management product is the FICO TRIAD! Customer Manager. The Company markets and sells TRIAD end-user software licenses, maintenance, consulting services, and strategy designs and evaluation. The Company's fraud management products improve the Company's clients' profitability by predicting the likelihood that a given transaction or customer account is experiencing fraud.

The Company's solutions are designed to detect and prevent a range of fraud and risk types across multiple industries, including credit and debit payment card fraud; e-payment fraud; deposit account fraud; technical fraud and bad debt; healthcare fraud; Medicaid and Medicare fraud, and property and casualty insurance claims fraud, including workers' compensation fraud. FICO fraud solutions protect financial institutions, insurance companies and government agencies from losses and damaged customer relationships caused by fraud and related criminal behavior.

FICO Fraud Predictor with Merchant Profiles is used in conjunction with Falcon Fraud Manager on payment card monitoring for credit and debit to improve fraud detection rates through the inclusion of merchant profiles. In addition to the Falcon products, the Company offers FICO Card Alert Service. Card Alert Service is a solution for fighting ATM debit fraud. The Card Alert Service identifies counterfeit payment cards and reports them to issuers. The Company offers FICO Economic Impact Service, which uses time series modeling of the macro economy to allow lenders to forecast future credit risk performance based on their views of the economy. Adeptra's software as a service (SaaS) platform enables financial services institutions and other businesses to take advantage of the explosion in mobile communication in order to manage risk, fight fraud and improve the customer experience, all in real time.

The Company competes with Acxiom, Epsilon, Equifax, Experian, Harte-Hanks, InfoUSA, KnowledgeBase, Merkle, TargetBase, CGI, NICE Systems, BAE, SAS, ACI Worldwide, Emdeon, Ingenix, ViPS, MedSt! at, Veris! k Analytics and IBM.

Scores

The Company develops credit scores based on third-party data. The Company's FICO Scores are used in most United States credit decisions, by the banks and credit card organizations, as well as by mortgage and auto loan originators. These scores provide a consistent and objective measure of an individual's credit risk. Credit grantors use the FICO Scores to prescreen candidates for solicitation, to evaluate applicants for new credit and to review existing accounts. The FICO Scores are calculated based on scoring models and implemented on third-party data. The version of the FICO Score for United States and Canadian lenders is the FICO 8 Score. The Company's other solutions include The FICO Credit Capacity Index and The FICO Economic Impact Index.

The Company competes with Experian and Experian-Scorex (U.S. partner), TransUnion and TransUnion International, Equifax, VantageScore, CRIF, LexisNexis and ChoicePoint.

Tools

The Company provides software products that businesses use to build their own tailored Decision Management applications. In contrast to its packaged Applications developed for specific industry applications, the Company�� Tools support the addition of Decision Management capabilities to virtually any application or operational system. These tools are sold as licensed software, and can be used by themselves or together to advance a client�� Decision Management initiatives. The Company uses these tools as common software components for its own Decision Management applications. The principal products offered are software tools include Rules Management, Predictive Modeling and Optimization.

The Company competes with IBM, SAS, Pegasystems and Angoss.

Advisors' Opinion:

• [By WWW.DAILYFINANCE.COM]

  Jupiterimages.com When it comes to understanding your credit, it can feel as complicated as trying to solve a Rubik's cube. Frustrated by this confusion, many consumers neglect their credit, which can have a devastating impact on their financial futures. A Consumer Action study recently revealed that 27 percent of Americans have never checked their credit report. That's alarming, because it's estimated that a large numbers of consumers have errors on their credit reports that could damage their credit. I found this out several years ago when I found an error -- a canceled account that was being reported as delinquent -- hurting my credit. In my research, I have identified three sneaky things that are hurting other people's credit, too. Surprisingly, they could be fixed in 15 minutes or less. First, you need to get your credit report, and you should go to AnnualCreditReport.com. From this site, you can request your free credit report once a year from the three major credit reporting agencies -- (Equifax (EFX), Experian (EXPGY) and TransUnion). You can also access your credit score there, but you'll have to pay a small fee. To get a free credit score, you can go to Credit.com or Creditkarma.com. Keep in mind that these two as well as a lot of other free sites offer a consumer education score, which isn't your actual FICO (FICO) score. This confused even me when I sought to find my real credit score. Your FICO score changes daily, so getting your credit scores from these free sites will give you a good gauge of approximately what your credit score is. 1. Wrong Information The wrong personal information on your credit report could hurt your credit. This could be things like your name, your home address, where you've worked in the past or even your Social Security number. How does a wrong address hurt your credit? Your information may be mixed up with someone else's, especially if you have a common name, or are a "Jr." or "Sr." Or it could indicate identity th

• [By Dan Caplinger]

  A recent study from Fair Isaac's (NYSE: FICO  ) FICO took a look at the demographics of credit card use lately. What they found is that outstanding credit card debt among 18- to 29-year-olds dropped from just over $3,000 in late 2007 to a bit over $2,000 last October. That move comes as part of a broader reduction in overall indebtedness, with drops in outstanding mortgage, auto, and most other debt more than offsetting a substantial rise in student-loan debt. Even more surprisingly, the proportion of young adults going without credit cards entirely has risen to nearly one in six, almost double the level from late 2005.

Best Life Sciences Companies To Buy Right Now: BNP Paribas SA (BNP)

BNP Paribas SA is a France-based bank group with four core businesses: Retail Banking, Corporate & Investment Banking, Investment Solutions and Other Activities. Retail Banking comprises the French retail banking division, Banca Nazionale del Lavoro in Italy, BeLux Retail Banking, Europe-Mediterranean, all BNP Paribas Group retail banking businesses out of Euro Zone: in the United States, in Asia, in the Mediterranean Basin and Africa, in Turkey, Central and Eastern Europe, personal finance and equipment solutions. The Corporate & Investment Banking business provides to its clients financing, advisory and capital markets services. The Investment Solutions division offers private banking, asset management, securities services, real estate and insurance services. In November 2013, the Company launched 'Hello Bank!', a mobile, digital bank operating in France, Belgium and Germany. Advisors' Opinion:

• [By Namitha Jagadeesh]

  BNP Paribas SA (BNP), Societe Generale SA (GLE) and Credit Agricole SA (ACA), France�� largest banks by market value, reported second-quarter profit that exceeded analysts��estimates. Paris-based Societe Generale, which said income more than doubled from a year earlier, trades at 10.8 times projected earnings, 64 percent below its 2009 high. Credit Agricole trades at 8.6 times projected profit and BNP Paribas at 10.7 times, according to data compiled by Bloomberg.

Best Life Sciences Companies To Buy Right Now: Glacier Media Inc (GLMFF.PK)

Glacier Media Inc. (Glacier) is an information communications company focused on the provision of information and related services through print and digital media. Glacier has two segments: the newspaper and trade information markets and the business and professional information markets. The operations in the newspaper and trade information group include the Western Producer Publications and Farm Business Communications agricultural information group, Business In Vancouver Media Group, the JuneWarren-Nickle�� Energy Group, the Business Information Group, and the Glacier Newspaper Group. Its operations in the business and professional information group include Specialty Technical Publishers, CD-Pharma, Eco Log and a joint venture interest in Fundata. In November 2011, the Company acquired a 50% interest in InfoMine Inc. In November 2011, the Company acquired Canada�� Outdoor Shows Limited. In December 2011, it acquired Postmedia Network Inc.'s community newspapers in British Columbia. Advisors' Opinion:

• [By Mike Arnold]

  Shares of Glacier Media (GLMFF.PK)(GVC.TO) ("Glacier" or "the company") are cold product in this market of stocks, trading at decade lows after a summer sell-off. Famed value investor Walter Schloss preferred buying stocks not at 52-week lows, but at multi-year lows. If Mr. Schloss were here with us today, I suspect he'd be taking a look at Glacier shares.

Best Life Sciences Companies To Buy Right Now: Alliance Holdings GP L.P.(AHGP)

Alliance Holdings GP, L.P., through its subsidiaries, produces and markets coal primarily to utilities and industrial users in the United States. It produces a range of steam coal with varying sulfur and heat contents. The company operates nine underground mining complexes in Illinois, Indiana, Kentucky, Maryland, and West Virginia. As of December 31, 2010, it had approximately 697.4 million tons of proven and probable coal reserves in Illinois, Indiana, Kentucky, Maryland, Pennsylvania, and West Virginia. In addition, the company leases land; and operates a coal loading terminal, with a capacity of 8.0 million tons with ground storage of approximately 60,000 to 70,000 tons, on the Ohio River at Mt. Vernon, Indiana. Further, it engages in purchasing and selling coal; and providing services, including ash and scrubber sludge removal, coal yard maintenance, and arranging alternate transportation services. Alliance GP, LLC, serves as the general partner of the company. Allian ce Holdings GP, L.P. is based in Tulsa, Oklahoma.

Advisors' Opinion:

• [By Seth Jayson]

  Calling all cash flows
  When you are trying to buy the market's best stocks, it's worth checking up on your companies' free cash flow once a quarter or so, to see whether it bears any relationship to the net income in the headlines. That's what we do with this series. Today, we're checking in on Alliance Holdings GP (Nasdaq: AHGP  ) , whose recent revenue and earnings are plotted below.

Best Life Sciences Companies To Buy Right Now: James River Coal Company(JRCC)

James River Coal Company, through its subsidiaries, engages in mining, processing, and selling thermal and metallurgical coal in eastern Kentucky, southern West Virginia, and southern Indiana. It conducts its mining operations in Bell County, Bledsoe, Blue Diamond- Buckeye, Blue Diamond-Leatherwood, Hampden, McCoy Elkhorn, Laurel Mountain, and Triad mining complexes. As of December 31, 2011, the company had 8 mining complexes, including 25 underground mines, 12 surface mines, and 14 preparation plants, as well as controlled approximately 362.8 million tons of proven and probable coal reserves in Central Appalachia and Midwest regions. It sells its coal to utility, steel, and industrial markets. The company was founded in 1988 and is headquartered in Richmond, Virginia.

Advisors' Opinion:

• [By Dan Caplinger]

  James River Coal (NASDAQ: JRCC  ) will release its quarterly report on Friday, and the hard-hit coal producer doesn't look likely to escape the big losses that have plagued it for a long time. With analysts seeing James River Coal earnings stuck in the red for the foreseeable future, investors have to wonder how much longer the company can sustain ongoing losses of this magnitude.

• [By Roberto Pedone]

  Another under-$10 energy player that's starting to move within range of triggering a near-term breakout trade is James River Coal (JRCC), which is engaged in mining, processing and selling thermal and metallurgical coal through eight active mining complexes located throughout eastern Kentucky, southern West Virginia and southern Indiana. This stock has been hit hard by the sellers so far in 2013, with shares off by 38%.

  If you take a look at the chart for James River Coal, you'll notice that this stock has been trending sideways for the last two months inside of a consolidation pattern, with shares moving between $1.70 on the downside and $2.32 on the upside. Shares of JRCC are now starting to trend back above its 50-day moving average of $1.94 a share. That move is quickly pushing JRCC within range of triggering a near-term breakout trade above the upper-end of its recent sideways trading chart pattern.

  Market players should now look for long-biased trades in JRCC if it manages to break out above some near-term overhead resistance levels at $2.20 to $2.32 a share and then once it clears its 200-day moving average at $2.48 a share with high volume. Look for a sustained move or close above those levels with volume that registers near or above its three-month average volume of 1.16 million shares. If that breakout triggers soon, then JRCC will set up to re-test or possibly take out its next major overhead resistance levels at $2.88 to $3.50 a share, or possibly even $4 a share.

  Traders can look to buy JRCC off any weakness to anticipate that breakout and simply use a stop that sits right below some key near-term support levels at either $1.74 or at $1.70 a share. One can also buy JRCC off strength once it clears those breakout levels with volume and then simply use a stop that sits a comfortable percentage from your entry point.

• [By Dimitra DeFotis]

  Alpha Natural Resources�(ANR) and�James River Coal�(JRCC) each rose nearly 12%. The largecap U.S. coal players also rallied: Arch Coal�(ACI) was up 10%,�Peabody Energy�(BTU) jumped nearly 9% . �